Mereo Biopharma Group Plc ADR (NASDAQ:MREO) price closed lower on Friday, April 12, dropping -0.73% below its previous close.
A look at the daily price movement shows that the last close reads $2.74. The company’s 5Y monthly beta was ticking 0.78. Taking into account the 52-week price action we note that the stock hit a 52-week high of $4.36 and 52-week low of $0.92. The stock subtracted -14.73% on its value in the past month.
Mereo Biopharma Group Plc ADR, which has a market valuation of $380.96 million, is expected to release its quarterly earnings report Mar 29, 2024 – Apr 02, 2024.
Revisions to the company’s EPS highlights a short term direction of a stock’s price movement, which in the last 7 days came up with no upward and no downward reviews. On the technical perspective front, indicators give MREO a short term outlook of Hold on average. Looking at the stock’s medium term indicators we note that it is averaging as a 50% Buy, while an average of long term indicators are currently assigning the stock as 50% Buy.
The overview shows that MREO’s price is at present -12.78% off the SMA20 and -22.14% from the SMA50. The Relative Strength Index (RSI) metric on the 14-day timeframe is pointing at 30.69, with weekly volatility standing at 6.50%. The indicator jumps to 6.36% when calculated based on the past 30 days. Mereo Biopharma Group Plc ADR (NASDAQ:MREO)’s beta value is holding at 0.81, while the average true range (ATR) indicator is currently reading 0.21. An analysis of the Mereo Biopharma Group Plc ADR (NASDAQ:MREO) stock in terms of its daily trading volume indicates that the 3-month average is 1.74 million.
Current records show that the company has 140.06M in outstanding shares. The insiders’ percentage holdings are 0.00% of outstanding shares while the percentage share held by institutions stands at 61.40%. But the 17.75% upside, the stock’s price has registered year-to-date as of last trading, will likely reignite investor interest given the prospect of it rallying even higher.
